Antithrombotic treatment in neonates and children
Despite the increasing incidence of venous thromboembolic disease in pediatric patients, it remains a rare complication in childhood. Particularly neonates and adolescents are at risk for development of venous thrombosis. Spontaneous thrombotic events are sporadic, the majority of children have multiple coexisting risk factors, including central venous catheter, asphyxia, congenital heart disease, infection, malignancy, surgery and hypovolemia. Most thrombi are diagnosed by ultrasonography. Recommendations for management of pediatric thrombosis are typically extrapolated from adult studies, despite many differences between adults and children, including developmental hemostasis. This review will focus on the management of venous thrombosis in neonates and children, and discuss the use of the available antithrombotic agents in both age categories with reference to those differences.
|Keywords||Anticoagulants, Thrombolytic therapy, Venous thrombosis|
|Persistent URL||dx.doi.org/10.23736/S0026-4946.17.05131-3, hdl.handle.net/1765/104320|
van Ommen, C.H. (2018). Antithrombotic treatment in neonates and children. Minerva Pediatrica (Vol. 70, pp. 67–78). doi:10.23736/S0026-4946.17.05131-3